Moderna’s Melanoma Vaccine Trial Marks a Turning Point for mRNA Cancer Treatment

Moderna’s experimental melanoma vaccine delivered a strong late‑stage trial result this week, sending the company’s share price soaring and signaling a potential shift in how cancer may be treated in the years ahead. The therapy, developed with Merck, is part of a growing class of personalized mRNA cancer vaccines designed to train the immune system...